Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

New investor Aperture joins in for Yaupon’s $14.4mm Series D round

Executive Summary

Rare cancer drug developer Yaupon Therapeutics Inc. has raised $14.4mm in Series D financing from first-time backer Aperture Venture and existing investors Vivo Ventures, Palo Alto Investors, and Burrill & Co. The money will support the company’s lead candidate, topical mechlorethamine gel, as the FDA reviews the NDA (which was filed just weeks ago) for stage I-IIa mycosis fungoides, the most common form of cutaneous T-cell lymphoma.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies